Purpose: To study the effect of intravitreal injection of bevacizumab on central macular thickness in retinal vein occlusion patients at a tertiary care centre of North India. Material and methods: A retrospective, data based study was carried out on 89 patients of acute retinal vein occlusion, including 35 cases of CRVO and 54 cases of BRVO, presented to our OPD over a period of 10 years. All cases included in this study received intravitreal injection of bevacizumab (2.5mg/0.1ml) at presentation and were followed up every month post-injection to record any change in BCVA and CMT. Results: The mean age of patients in BRVO and CRVO group was 56.81+7.02 and 57.02+7.8 years. Mean CMT at baseline was 449.16+121.28 µm in BRVO group which significantly reduced to 304.84+78.14 µm at 1 month post-injection follow up visit. In CRVO group, mean CMT at baseline was 680.17+ 175.12 µm which significantly reduced to 399.97+88.43 µm at 1 month post injection. Mean BCVA in BRVO group at baseline was 0.96+0.36 LogMAR which got significantly improved to 0.65 +0.24 LogMAR at 1st month post-injection while in CRVO group, mean BCVA at baseline was 1.59+0.48 LogMAR which got significantly improved to 1.02+0.34 LogMAR at 1st month post-injection. Conclusion: Intravitreal bevacizumab is beneficial in the improvement of BCVA and treatment of macular edema due to venous occlusion. However, any beneficial effect on visual acuity and reduction of macular edema on OCT seen initially starts weaning off after 2 months and gradually reaching to baseline value at 6 months.